297 related articles for article (PubMed ID: 7937878)
1. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.
Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G
Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878
[TBL] [Abstract][Full Text] [Related]
2. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
Sun LQ; Wang L; Gerlach WL; Symonds G
Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
Ramezani A; Joshi S
Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Moloney murine leukaemia virus by a retroviral vector, LNL6, carrying ribozymes targeted to the 5' non-coding sequence.
Lowenstein P; Symonds G
J Gen Virol; 1997 Oct; 78 ( Pt 10)():2587-90. PubMed ID: 9349479
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA.
Lo KM; Biasolo MA; Dehni G; Palú G; Haseltine WA
Virology; 1992 Sep; 190(1):176-83. PubMed ID: 1529527
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s).
Cohli H; Fan B; Joshi RL; Ramezani A; Li X; Joshi S
Antisense Res Dev; 1994; 4(1):19-26. PubMed ID: 7914762
[TBL] [Abstract][Full Text] [Related]
8. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
[TBL] [Abstract][Full Text] [Related]
9. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
Zhou C; Bahner I; Rossi JJ; Kohn DB
Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
[TBL] [Abstract][Full Text] [Related]
10. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
[TBL] [Abstract][Full Text] [Related]
11. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
[TBL] [Abstract][Full Text] [Related]
12. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
Sena-Esteves M; Hampl JA; Camp SM; Breakefield XO
J Gene Med; 2002; 4(3):229-39. PubMed ID: 12112640
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
[TBL] [Abstract][Full Text] [Related]
14. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA.
Sullenger BA; Cech TR
Science; 1993 Dec; 262(5139):1566-9. PubMed ID: 8248806
[TBL] [Abstract][Full Text] [Related]
15. Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication.
Kechli AM; Freiden PJ; Rossi JJ; Brenner MK; Choueiry MA; Garcia JV; Slobod KS
Hum Gene Ther; 1998 Mar; 9(4):587-90. PubMed ID: 9525319
[TBL] [Abstract][Full Text] [Related]
16. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme.
Weerasinghe M; Liem SE; Asad S; Read SE; Joshi S
J Virol; 1991 Oct; 65(10):5531-4. PubMed ID: 1895402
[TBL] [Abstract][Full Text] [Related]
17. Ribozyme mediated destruction of influenza A virus in vitro and in vivo.
Tang XB; Hobom G; Luo D
J Med Virol; 1994 Apr; 42(4):385-95. PubMed ID: 8046429
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus.
Xing Z; Mahadeviah S; Whitton JL
Antisense Res Dev; 1995; 5(3):203-12. PubMed ID: 8785476
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of stem-loops in the RNA packaging signal of the Moloney murine leukemia virus.
Fisher J; Goff SP
Virology; 1998 Apr; 244(1):133-45. PubMed ID: 9581786
[TBL] [Abstract][Full Text] [Related]
20. Monitoring retroviral RNA dimerization in vivo via hammerhead ribozyme cleavage.
Pal BK; Scherer L; Zelby L; Bertrand E; Rossi JJ
J Virol; 1998 Oct; 72(10):8349-53. PubMed ID: 9733882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
